(NASDAQ: COGT) Cogent Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.97%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.99%.
Cogent Biosciences's revenue in 2025 is $0.On average, 6 Wall Street analysts forecast COGT's revenue for 2026 to be $5,894,116,284, with the lowest COGT revenue forecast at $335,281,910, and the highest COGT revenue forecast at $15,897,950,585. On average, 5 Wall Street analysts forecast COGT's revenue for 2027 to be $31,626,025,002, with the lowest COGT revenue forecast at $8,692,183,527, and the highest COGT revenue forecast at $85,273,365,878.
In 2028, COGT is forecast to generate $47,513,078,924 in revenue, with the lowest revenue forecast at $28,753,217,833 and the highest revenue forecast at $81,836,726,297.